8
May
2023
Creating a New Class of Medicines: John Maraganore on The Long Run
Today’s guest on The Long Run is John Maraganore. John is best known as the former CEO of Alnylam Pharmaceuticals, the RNA interference drug developer. He spent 19 years there as CEO, before stepping down at the end of 2021. Alnylam figured out how to make a new therapeutic modality — gene-silencing with double-stranded oligonucleotide therapies. Alnylam’s technology has now... Read More
4
May
2023
Lilly’s Alzheimer’s Win, Astellas Breaks Out Checkbook, & a RSV Vaccine First
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
May
2023
Preserving the Biotech Social Contract – We Should All Be Pitching In
[Editor’s Note: This is a preface by Jeremy Levin supporting the following essay by Steve Potts.] Biotech is an industrial tapestry woven together by remarkable people with deep intellect, determination, passion, and bravery all driven to create the next and best medicine. Underpinning it is an immense and complex infrastructure including capital formation, regulatory processes, patient advocacy, policy making, health... Read More
27
Apr
2023
Big Week for RNA Medicines, BMS Gets a New Boss, and a Microbiome First
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Apr
2023
Orbital Secures $270M to Make New RNA Medicines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Apr
2023
Vedanta Biosciences Secures $106.5M to Advance Oral Microbiome Therapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Apr
2023
Gene Editing Therapies Delivered In Vivo: Ensoma’s Emile Nuwaysir on The Long Run
Today’s guest on The Long Run is Emile Nuwaysir. Emile is the CEO of Boston-based Ensoma. Ensoma is developing gene-editing therapies that can be delivered in a single shot, in vivo, inside the body. The name is derived from the Greek word for ‘in the body.’ The basic idea is to make these gene editing medicines so they can be... Read More
20
Apr
2023
The Supreme Court and the FDA
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Apr
2023
Abdera Gets $142M To Make Potent, Safe, Radioantibodies for Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Apr
2023
The “D” Word: Delivery is the Next Frontier for Genetic Medicines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Apr
2023
The FDA’s Hour of Need, Digital Tx Pioneer Shuts Down, & HSBC Hires SVB Vets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Apr
2023
Aer Therapeutics Gets $36M Series A to Break Down Mucus in Lungs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Apr
2023
The Frontier of Epigenetic Editing: Chroma CEO Catherine Stehman-Breen
Today’s guest on The Long Run is Catherine Stehman-Breen. Catherine is the CEO of Boston-based Chroma Medicine. Chroma is working on therapies that control gene expression through epigenetic editing. People have heard a lot about editing of the genome with CRISPR, and then subsequent refinements of the technology known as base editing and prime editing. The question at Chroma is... Read More
12
Apr
2023
Function Gets $28M to Make Personalized Cancer Genomics to the Next Level
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Apr
2023
In Support of FDA’s Authority to Regulate Medicines
On Friday, April 7, a federal judge with no scientific training fundamentally undermined the bipartisan authority granted by Congress to the Food and Drug Administration to approve and regulate safe, effective medicines for every American. District Judge Matthew Kacsmaryk issued a decision that overturns the FDA’s 23-year-old approval of mifepristone, the primary medicine used in abortion and miscarriage care, and... Read More
8
Apr
2023
Tech, Pharma, and the Uneven Distribution of the AI-Enabled Future
The worlds of technology and entrepreneurship are captivated by recent advances in generative AI and large language models (LLMs). The arrival of ChatGPT, developed by OpenAI (a startup partnered with Microsoft), caused Google to declare a “Code Red,” akin to “pulling the fire alarm,” the New York Times explained. The latest class of startups at Y Combinator are reportedly flocking... Read More
6
Apr
2023
CRISPR, Vertex Seek FDA Milestone, Canaan Pulls in $850M, & Cutting Out the Middleman
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Apr
2023
Translating CRISPR Gene-Editing into a Groundbreaking Cell Therapy
A little more than 10 years have passed since the discovery of CRISPR gene editing. It’s been a whirlwind development for science and medicine. We are now on the cusp of seeing the first medicine based on this powerful technology win approval from regulators in the US and Europe. It’s exagamglogene autotemcel (exa-cel), a cell therapy developed by CRISPR Therapeutics... Read More
2
Apr
2023
New Book Contemplates How Generative AI Will Serve Man
In 1935, Astounding Science — the premier science fiction magazine of the day, and perhaps ever — published “Proxima Centauri.” It was a short story envisioning an encounter between a voyaging earth spacecraft and a ship from a nearby star system. Written by Murray Leinster (William Fitzgerald Jenkins), the tale features the original use of the phrase “first contact” in... Read More
30
Mar
2023
Jan Skvarka, former Trillium CEO, on Driving a Turnaround
Jan Skvarka isn’t a household name in biotech. Maybe he should be. Skvarka was previously the CEO of Trillium Therapeutics, where he led a remarkable turnaround of the Canadian small cap biotech into a leading immune oncology player. Trillium had a market capitalization of $16 million when he started. Over the next two years, he led it to a $2.26... Read More